In a report released yesterday, Luca Issi from RBC Capital maintained a Buy rating on Alnylam Pharma (ALNY – Research Report), with a price target of $235.00. The company’s shares closed yesterday at $150.31.
Issi covers the Healthcare sector, focusing on stocks such as Alnylam Pharma, Moderna, and BioMarin Pharmaceutical. According to TipRanks, Issi has an average return of -24.0% and a 19.59% success rate on recommended stocks.
In addition to RBC Capital, Alnylam Pharma also received a Buy from Chardan Capital’s Keay Nakae in a report issued yesterday. However, on April 25, Leerink Partners maintained a Hold rating on Alnylam Pharma (NASDAQ: ALNY).
Based on Alnylam Pharma’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $439.72 million and a GAAP net loss of $137.87 million. In comparison, last year the company earned a revenue of $335.03 million and had a GAAP net loss of $207.49 million
Based on the recent corporate insider activity of 29 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of ALNY in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Alnylam Pharma (ALNY) Company Description:
Alnylam Pharmaceuticals, Inc. operates as biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics. It is the translation of RNAi as a new class of innovative medicines with a core focus on RNAi therapeutics for the treatment of genetically defined diseases. The company was founded by John Kennedy Clarke, Paul R. Schimmel and Phillip A. Sharp on June 14, 2002 and is headquartered in Cambridge, MA.
